跳至主要内容
临床试验/NCT02804334
NCT02804334终止不适用

The Role of Molecules in Blood Cells for Diagnosing Bipolar Disorders

University Hospitals Cleveland Medical Center1 个研究点 分布在 1 个国家目标入组 29 人开始时间: 2016年6月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
29
试验地点
1
主要终点
Sensitivity of ~45 molecules in blood cells of patients with bipolar I or II disorder versus healthy controls

研究概览

简要总结

The goal of this project is to study ~45 molecules in blood cells that may differentiate patients with bipolar disorder from healthy controls.

详细描述

There is one study visit for this research protocol. Participants may complete this visit on the day that they sign consent. If there is an upcoming blood draw already scheduled for the participant, within the clinical research trial in which they are enrolled, they may decide to wait until then to receive their blood draw. In addition, if a subject has completed the protocol specific monitoring labs within the past 30 days, either for clinical or research purposes, they do not have to be repeated.

After obtaining the informed consent, all potential research participants will be assessed with a systemic clinical interview and a structured interview with the Mini-International Neuropsychiatric Interview (MINI). Psychiatric assessments will be administered to all participants, both healthy controls and participants diagnosed with bipolar disorder (BD). All eligible participants will also complete a Clinical Record Form. The form includes demographics, previous treatment history, the number of previous episodes, family history, and other historical correlates.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Sensitivity of ~45 molecules in blood cells of patients with bipolar I or II disorder versus healthy controls

时间窗: Day 1

Specificity of ~45 molecules in blood cells of patients with bipolar I or II disorder versus healthy controls

时间窗: Day 1

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Keming Gao

Clinical Director, Mood Disorders Program, UH Cleveland Medical Center

University Hospitals Cleveland Medical Center

研究点 (1)

Loading locations...

相似试验